Polyrizon launches $4M registered direct offering and private placement

Polyrizon Ltd. (NASDAQ: PLRZ), a development-stage biotech company based in Raanana, Israel, announced it has entered into definitive agreements with a single institutional investor for a registered direct offering and concurrent private placement, with aggregate gross proceeds expected to reach approximately $4.0 million.

The transactions involve the sale of 333,333 units, each consisting of one ordinary share, or one pre-funded warrant to purchase one ordinary share, and one common warrant to purchase one ordinary share. The combined offering price is $12.00 per unit, or $11.99999 per pre-funded unit. In the registered direct offering, the company agreed to sell 232,500 ordinary shares and 30,000 pre-funded warrants. The concurrent private placement includes 70,833 PIPE pre-funded warrants and 333,333 PIPE common warrants, with common warrants carrying an exercise price of $12.00 per share.

The transactions are expected to close on or about September 4, 2026, subject to customary closing conditions. The company stated it intends to use net proceeds for general corporate purposes and working capital. Upon completion, and assuming exercise of all pre-funded warrants issued in the offering, Polyrizon will have 2,806,233 ordinary shares issued and outstanding.

The registered direct offering is being made pursuant to an effective shelf registration statement on Form F-3 previously filed with the U.S. Securities and Exchange Commission and declared effective on December 3, 2025. Aegis Capital Corp. is acting as exclusive placement agent for the offerings.

You May Also Be Interested In

• DEFSEC Technologies (DFSC) files for 4.05M share offering by selling stockholders
• Wellchange Holdings to execute 1-for-5 reverse stock split Sept. 8
• XTEND confirms $60M cash received as JFB merger nears close